PDS Biotechnology Corporation (PDSB)

4,0200 +0,2450 (+6,49%) Al cierre: 04:00PM EDT

PDS Biotechnology Corporation

303A College Road East
Princeton, NJ 08540
United States
800 208 3343
https://www.pdsbiotech.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 25

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Frank K. Bedu-Addo Ph.D.	President, CEO & Director	853,85k	N/A	1965
Dr. Gregory L. Conn Ph.D.	Chief Scientific Officer	194,67k	N/A	1955
Mr. Lars Robert Boesgaard M.B.A.	Principal Financial & Accounting Officer and CFO	N/A	N/A	1970
Mr. Stephan Toutain M.B.A., M.S.	Chief Operating Officer	N/A	N/A	1966
Dr. Joe J. Dervan	VP of Research & Development	N/A	N/A	N/A
Ms. Deanne Randolph	Head of Investor Relations	N/A	N/A	N/A
Mr. Spencer Brown J.D.	Senior VP, General Counsel, Corporate Secretary & Chief Compliance Officer	N/A	N/A	1970
Dr. Kirk V. Shepard M.D.	Chief Medical Officer	N/A	N/A	1952
Ms. Janetta Trochimiuk	Controller	N/A	N/A	1963

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

Gobierno corporativo

El ISS Governance QualityScore de PDS Biotechnology Corporation, a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.